Chronicles in drug discovery
other
OA: closed
public-domain-us
AI-generated summary
This paper reviews recent findings on IDO inhibitors for cancer, gamma-secretase inhibitors for Alzheimer's, ERbeta agonists for POF and other disorders, and phospholipase A2 inhibitors for inflammatory diseases.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
New brief reports this month describe five timely topics: IDO inhibitors have demonstrated antitumor properties by increasing immune response to tumors and improving chemotherapy effectiveness. One of the current therapeutic efforts for Alzheimer's disease is directed towards blocking the gamma-secretase activity, thus reducing amyloid-beta production. Patients with premature ovarian failure (POF), at present mainly treated with hormone replacement therapy, are belated for novel treatment options. Selective ERbeta agonists are anticipated to emerge as therapeutics for the treatment of various diseases including inflammatory bowel syndrome, endometriosis, dementia and cognitive disorders. Phospholipase A2 inhibitors specific for enzyme isoforms are actively studied as potential antiallergic/antiasthmatic drugs, antiarthritic agents and therapeutics for atherosclerosis.
My notes (saved in your browser only)
Condition tags
MeSH descriptors
Citation neighborhood (no data yet)
We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.
Source provenance
- europepmc
- last seen: 2026-08-18T06:10:16.649438+00:00
- pubmed
- last seen: 2026-05-13T22:15:35.797702+00:00
- unpaywall
- last seen: 2026-05-14T19:30:52.867331+00:00
License: public-domain-us
· commercial use OK
· attribution required
Courtesy of the U.S. National Library of Medicine
Courtesy of the U.S. National Library of Medicine